Novel Chemotherapies for Metastatic Papillary, Follicular, or Hurthle Cell Thyroid Cancer

Session 142 from: #ThyCa20: Novel chemotherapies for patients with metastatic papillary, follicular, or Hurthle cell thyroid cancer with Maria E. Cabanillas, MD, Oncologic Endocrinologist.
Maria E. Cabanillas, MD, is an oncologic endocrinologist and associate professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is the faculty director of clinical research in the Department of Endocrine Neoplasia at MD Anderson. As a clinician and clinical researcher, Dr. Cabanillas treats both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic. Her research focus is in advanced and aggressive thyroid cancer and molecular targeted therapies and immunotherapy. She is a principal investigator on several clinical trials for treating advanced disease and has been a member of and currently serves on the board of directors of the International Thyroid Oncology Group (ITOG). She is a ThyCa medical advisor.
Learn more about thyroid cancer on our website: www.ThyCa.org